首页> 外文期刊>Cancer science. >Recent progress in pathogenesis and management of colorectal cancer. Eighteenth International Symposium of the Hiroshima Cancer Seminar, November 2008.
【24h】

Recent progress in pathogenesis and management of colorectal cancer. Eighteenth International Symposium of the Hiroshima Cancer Seminar, November 2008.

机译:大肠癌的发病机理和治疗的最新进展。 2008年11月,第18届广岛癌症研讨会国际研讨会。

获取原文
获取原文并翻译 | 示例
           

摘要

This symposium presented recent progress of the pathogenesis and treatment of colorectal cancer (CRC). Field cancerization by modified stem cells may be the earliest changes associated with CRC. CD34+-immature myeloid cells are deeply involved in CRC invasion. Inflammatory mediators stimulate cancer progression. We must strive for a better understanding of the molecular mechanisms responsible for this connection. Serial analysis of gene expression data analysis has identified novel biomarkers for cancer detection and possible prognosis. Better endoscopic techniques are suitable for early detection and resection of colonic lesions. Chemoprevention of CRC using sulindac and aberrant crypt foci as a clinical endpoint have shown glutathione S-transferase pi as a possible new target. A new drug delivery system using nanoparticles is being developed with SN-38, a biologically active metabolite of irinotecan. Survival of Japanese male patients with CRC is the best in the world due to lymph node dissection andsurveillance. The use of laparoscopic surgery has increased, especially for advanced cancer. A treatment trial by the Sanin Study Group suggests that modified 5-fluorouracil and leucovorin with oxaliplatin treatment could be carried out in elderly patients. A great deal of information for understanding carcinogenesis and treatment has provided us with novel strategies for the management and prevention of CRC.
机译:本次研讨会介绍了大肠癌的发病机理和治疗的最新进展。修饰的干细胞引起的癌变可能是与CRC相关的最早变化。 CD34 +-未成熟的髓样细胞与CRC侵袭密切相关。炎性介质刺激癌症进展。我们必须努力更好地理解造成这种联系的分子机制。基因表达数据分析的系列分析已确定了用于癌症检测和可能预后的新型生物标志物。更好的内窥镜检查技术适用于结肠病变的早期发现和切除。使用舒林酸和异常隐窝灶作为临床终点的CRC的化学预防显示,谷胱甘肽S-转移酶pi是可能的新靶标。正在开发一种使用纳米颗粒的新型药物输送系统,该系统与伊立替康的生物活性代谢物SN-38结合使用。由于淋巴结清扫和监视,日本男性CRC患者的生存率是世界上最好的。腹腔镜手术的使用已经增加,特别是对于晚期癌症。 Sanin研究小组进行的一项治疗试验表明,老年患者可以使用奥沙利铂对5-氟尿嘧啶和亚叶酸进行改良。大量了解癌变和治疗的信息为我们提供了治疗和预防CRC的新策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号